|
Colonic Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
A wild-type p53 gene under control of the metallothionein MT-1 promoter was stably transfected into human colon tumor-derived cell line EB.
|
1584781 |
1992 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When AMPLICOR MTB results were compared with resolved results, i.e., a specimen grew M. tuberculosis or was obtained from a patient with a clinical diagnosis of tuberculosis, the sensitivity, specificity, positive predictive value, and negative predictive value for the AMPLICOR MTB test were 66.7, 99.6, 91.7, and 97.7%, respectively.
|
7665654 |
1995 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed an algorithm that can be used to make an initial choice of a probe (either Mycobacterium tuberculosis complex [MTB] or M. avium complex [MAC]) for use in testing respiratory specimens.
|
7665676 |
1995 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of Amplicor MTB test as adjunct to smears and culture for direct detection of Mycobacterium tuberculosis in the French Caribbean.
|
8727876 |
1996 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results support the use of AMPLICOR MTB for rapid diagnosis of tuberculosis in patients whose respiratory specimens are AFB smear positive.
|
8727880 |
1996 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The reliability of the Roche AMPLICOR Mycobacterium tuberculosis test (AMPLICOR MTB) for the diagnosis of pulmonary tuberculosis was evaluated by testing 956 respiratory specimens from 502 patients and comparing results with results by culture and medical history.
|
8727880 |
1996 |
|
Mycobacterium avium-intracellulare Infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two specimens from two patients with no clinical evidence of tuberculosis were AMPLICOR MTB positive and culture positive for Mycobacterium avium complex.
|
8727880 |
1996 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results confirm the reliability of the AMPLICOR MTB assay for direct detection of M. tuberculosis in AFB smear-positive sputum specimens and suggest a potential role in evaluating AFB smear-negative sputum specimens.
|
9154406 |
1997 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The reliability of the Roche Mycobacterium tuberculosis polymerase chain reaction (PCR) assay (AMPLICOR MTB) for the diagnosis of pulmonary tuberculosis was evaluated by testing expectorated sputum specimens from 187 inmates in Texas state prisons and comparing the results to culture and medical history.
|
9154406 |
1997 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A ligase chain reaction (LCR) DNA amplification method for the molecular diagnosis of Mycobacterium tuberculosis (Abbott LCx MTB) was evaluated in comparison with solid and liquid phase culture on 622 selected samples collected in two large Italian hospitals, of which 310 obtained from HIV-1 positive patients and 312 from HIV-negative individuals.
|
9579333 |
1998 |
|
Breast Carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The gene and phenotype frequencies of 5-MT I and 5-MT II were not significantly different in genomic DNA samples from a series of non-Hodgkin's lymphomas and breast cancer cases compared with DNA from normal subjects.
|
9694254 |
1998 |
|
Malignant neoplasm of breast
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The gene and phenotype frequencies of 5-MT I and 5-MT II were not significantly different in genomic DNA samples from a series of non-Hodgkin's lymphomas and breast cancer cases compared with DNA from normal subjects.
|
9694254 |
1998 |
|
Hodgkin Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The gene and phenotype frequencies of 5-MT I and 5-MT II were not significantly different in genomic DNA samples from a series of non-Hodgkin's lymphomas and breast cancer cases compared with DNA from normal subjects.
|
9694254 |
1998 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A positive LCx-MTB result in a smear negative specimen was 100% predictive that at least one of the case patients' specimens would yield M. tuberculosis.
|
9769266 |
1998 |
|
Tuberculosis, Pulmonary
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that the sensitivity of LCx-MTB in detecting M. tuberculosis DNA in respiratory tract specimens is similar to other DATs, that LCx-MTB is a reliable test for confirmation of TB in smear-positive patients and that LCx-MTB could be beneficial as a diagnostic step in smear-negative patients with a high suspicion of pulmonary TB.
|
9769266 |
1998 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to compare the results of a commercial assay based on the ligase chain reaction [(LCR) LCx Probe System MTB; Abbott, USA] with those of culture in liquid medium (Septi-Chek AFB; Becton-Dickinson, USA) and culture on the egg-based Löwenstein-Jensen solid medium for the direct detection of Mycobacterium tuberculosis complex in nonrespiratory specimens.
|
9923516 |
1998 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diverse population of MDR-MTB in Scotland, along with a low incidence of drug-resistant M. tuberculosis, has implications for the control of the organism and prevention of its spread.
|
10074516 |
1999 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The performance was evaluated of a fluorescence in situ hybridisation assay using peptide nucleic acid probes (Dako Probe MTB Culture Confirmation Test; Dako, Denmark) for identification of Mycobacterium tuberculosis complex (MTC) organisms and differentiation between tuberculous and non-tuberculous mycobacteria (NTM) in material taken directly from Bactec 12B (Becton Dickinson, USA) and MB/BacT (Organon Teknika, USA) bottles.
|
10746504 |
2000 |
|
Creutzfeldt-Jakob disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
A quantitative Western blot analysis also revealed that MT-I/II protein accumulated in CJD brain with a short disease duration, whereas MT-III in CJD brain with a long disease duration was statistically significantly reduced in comparison to the normal brains.
|
10940676 |
2000 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A new fluorescence in situ hybridization assay based on peptide nucleic acid probes (MTB and NTM probes targeting tuberculous and nontuberculous species, respectively) for the identification of Mycobacterium tuberculosis complex and differentiation between tuberculous and nontuberculous mycobacteria (NTM) was evaluated using Lowenstein-Jensen (LJ) solid cultures from 100 consecutive sputum samples and 50 acid-fast bacillus (AFB)-positive sputum samples as well as Mycobacteria Growth Indicator Tube (MGIT) liquid cultures from 80 AFB-positive sputum samples.
|
11230423 |
2001 |
|
AMYOTROPHIC LATERAL SCLEROSIS 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
We then investigated whether the clinical course of FALS mice could be modified by the reduced expression of MTs, by crossing the FALS mice with MT-I- and MT-II-deficient mice.
|
11298796 |
2001 |
|
Mammary Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The mt1 receptor, but not the MT2 receptor, is expressed in human breast tumor cell lines, and melatonin-induced growth suppression can be mimicked by the mt1 and MT2 agonist, AMMTC, and blocked by the antagonist, CBPT.
|
11888668 |
2002 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance of an IS6110-based PCR assay and the COBAS AMPLICOR MTB PCR system for detection of Mycobacterium tuberculosis complex DNA in human lymph node samples.
|
12149389 |
2002 |
|
Glaucoma, Primary Open Angle
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The 2 alleles of the MYOC.mt1 promoter polymorphism were equally distributed among patients with POAG and healthy control subjects.
|
12215093 |
2002 |
|
Glaucoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Testing for the MYOC.mt1 promoter polymorphism appears to be of no value in the evaluation of patients with glaucoma.
|
12215093 |
2002 |